#USA #cancer detection #Jersey City, NJ #WallachBeth #bioAffinity

WallachBeth Capital Announces bioAffinity Technologies' $3.25 Million Offering

Date: May 6, 2025
Location: Jersey City, NJ

WallachBeth Capital LLC, a prominent player in the field of capital markets and institutional execution services, has today unveiled the pricing details of bioAffinity Technologies, Inc.'s latest offering, which aims to raise approximately $3.25 million. This significant funding is crucial as bioAffinity focuses on developing noninvasive tests for the early detection of cancer, which is a critical need in the biomedical field.

The offering comprises 10,156,250 shares of bioAffinity’s common stock, alongside pre-funded warrants and additional warrants allowing for the purchase of up to 15,234,375 shares of common stock. The combined price for each share (or pre-funded warrant) and the accompanying warrants is set at $0.32. This structured financial move is geared towards enhancing bioAffinity's operational capacity to innovate in the medical device arena, particularly in cancer diagnostics.

The anticipated closing date for this offering is around May 7, 2025, provided that all customary closing conditions are satisfied promptly. WallachBeth Capital stands as the sole placement agent for this offering, showcasing its commitment to connecting innovative companies in healthcare with the resources they require to thrive.

This announcement underscores WallachBeth's dedication to investing in the healthcare sector, where financing often plays a crucial role in facilitating ground-breaking advancements. By providing effective capital solutions, WallachBeth Capital not only supports their clients but also contributes to the broader goal of improving patient outcomes through technology and innovation.

About bioAffinity Technologies

bioAffinity Technologies is at the forefront of developing diagnostic tools aimed at early cancer detection. Their noninvasive testing technology seeks to provide a safer, more accurate method for identifying cancer at its earliest stages, which could radically alter treatment success rates and patient prognoses. The funds garnered from this offering will be essential for advancing their research and development efforts.

Securities Registration

The securities being offered have been registered under a Form S-1 registration statement (File No. 333-286921) that has been previously filed and declared effective by the SEC. Thus, this offering will adhere meticulously to regulatory requirements, ensuring compliance and transparency in the financing process.

Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements which can be identified by terminology such as “expect,” “may,” “will,” and similar expressions. These statements express the company’s current expectations and are subject to risks and uncertainties that might cause actual results to differ significantly. Stakeholders are encouraged to consider these factors carefully when interpreting the potential outcomes related to the offering.

In conclusion, this offering not only represents a financial initiative but also signifies the cooperative efforts between healthcare innovators and financing experts, aimed at reshaping the future of cancer detection and improving patient care nationwide. By engaging in this offering, investors will play a part in supporting advancements that could potentially save lives in the near future.